Lung Cancer

Double immune checkpoint blockade in advanced NSCLC.

Immunotherapy-based options for patients with advanced non-small cell lung cancer (NSCLC) are increasing at an unprecedented pace, carrying the promise to prolong survival of this deadly disease. To maximize responses and extend...

Read More

Covid-19 and lung cancer: A greater fatality rate?

Currently there are no reported series determining the Covid-19 infected lung cancer patientĀ“s characteristics and outcome that allow us to clarify strategies to protect our patients. In our study we determine whether exists...

Read More